BioLineRx (NASDAQ:BLRX) Releases Quarterly Earnings Results

BioLineRx (NASDAQ:BLRX) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.04), Zacks reports. BioLineRx had a negative net margin of 99.58% and a negative return on equity of 5.61%. The company had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.36 million.

BioLineRx Price Performance

NASDAQ:BLRX opened at $3.37 on Thursday. BioLineRx has a one year low of $2.15 and a one year high of $7.77. The company has a market cap of $14.66 million, a P/E ratio of -19.82 and a beta of 1.42. The firm’s fifty day moving average price is $2.61 and its two-hundred day moving average price is $2.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.95 and a quick ratio of 1.78.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy”.

About BioLineRx

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.